Fred Aslan, President and CEO at Artiva Biotherapeutics, Inc. (ARTV), sold 34,444 shares at $2.73 ($91K) on 2025-08-15, disclosed to the SEC on 2025-08-18.
Scheduled sale ($91k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.13 | 4,472 | $10K | 10.4% |
| 2 | $2.73 | 25,500 | $70K | 76.1% |
| 3 | $2.75 | 4,472 | $12K | 13.4% |
| Total | $2.65 avg | 34,444 | $91K | 100% |
| Filing → |
| ARTV | SELL | 2026-09-09 | $256K | — | Filing → |
| ARTV | SELL | 2026-09-04 | $690K | — | Filing → |
| ARTV | SELL | 2026-05-19 | $244K | — | Filing → |